We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients.
- Authors
Kanda, Tatsuo; Imazeki, Fumio; Mikami, Shigeru; Kato, Keizo; Shimada, Noritomo; Yonemitsu, Yutaka; Miyauchi, Tomoo; Arai, Makoto; Fujiwara, Keiichi; Tsubota, Akihito; Takada, Nobuo; Nishino, Takayoshi; Takashi, Motohide; Sugiura, Nobuyuki; Kimura, Michio; Fukai, Kenichi; Yokosuka, Osamu
- Abstract
Advanced chronic hepatitis C patients with sustained virolological response by antivirals remain at risk for hepatocellular carcinoma (HCC). We investigated the incidence of HCC during and immediately after peginterferon-alfa-2a and ribavirin (RBV) treatment in patients with chronic hepatitis C in Japan. HCC was detected in 8 of 238 patients during and after these treatments (mean follow-up period: 572 ± 252 days). In conclusion, occurrence of HCC is not a rare event during and immediately after peginterferon-alfa-2a plus RBV treatment. In cases with cirrhosis, higher α-fetoprotein levels, old age, or a previous history of HCC treatment, clinicians should be especially alert for the possible development of HCC during and immediately after peginterferon-alfa-2a and RBV treatment. Clinicians should regularly check for the possible development of HCC even in chronic hepatitis C patients under treatment. Copyright © 2011 S. Karger AG, Basel
- Subjects
JAPAN; HEPATITIS C; VIRAL hepatitis; CANCER patients; LIVER cancer
- Publication
Oncology, 2011, Vol 80, Issue 5/6, p366
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000330549